The latest price target for Kyverna Therapeutics (NASDAQ:KYTX) was reported by Morgan Stanley on December 4, 2025. The analyst firm set a price target for $25.00 expecting KYTX to rise to within 12 months (a possible 145.10% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Kyverna Therapeutics (NASDAQ:KYTX) was provided by Morgan Stanley, and Kyverna Therapeutics maintained their overweight rating.

The last upgrade for Kyverna Therapeutics Inc happened on May 27, 2025 when HC Wainwright & Co. raised their price target to $5. HC Wainwright & Co. previously had a neutral for Kyverna Therapeutics Inc.

There is no last downgrade for Kyverna Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kyverna Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kyverna Therapeutics was filed on December 4, 2025 so you should expect the next rating to be made available sometime around December 4, 2026.

While ratings are subjective and will change, the latest Kyverna Therapeutics (KYTX) rating was a maintained with a price target of $20.00 to $25.00. The current price Kyverna Therapeutics (KYTX) is trading at is $10.20, which is out of the analyst’s predicted range.